Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
3.450
+0.020 (0.58%)
At close: Jun 12, 2026, 4:00 PM EDT
3.450
0.00 (0.01%)
After-hours: Jun 12, 2026, 7:09 PM EDT

Niagen Bioscience Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Niagen Bioscience stock has a consensus rating of "Strong Buy" and an average price target of $12.6. The average 1-year stock price forecast is 265.22% higher than the current stock price, while the lowest is $10 (+189.86%) and the highest is $18 (+421.74%).

Price Target: $12.6 (+265.22%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$10$12.6$12$18
Change+189.86%+265.22%+247.83%+421.74%

Analyst Ratings

The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingNov '25Dec '25Feb '26Mar '26Apr '26May '26
Strong Buy555555
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total555555

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$10
BuyMaintains$10+189.86%May 28, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$12$11
BuyReiterates$12$11+218.84%May 11, 2026
Unknown Analyst
Ladenburg Thalmann & Co.
No rating
Ladenburg Thalmann & Co.
Buy
Reiterates
$12
BuyReiterates$12+247.83%May 7, 2026
Roth MKM
Roth MKM
Buy
Reiterates
$13$12
BuyReiterates$13$12+247.83%May 7, 2026

Financial Forecast

Revenue This Year
142.28M
from 129.42M
Increased by 9.94%
Revenue Next Year
166.92M
from 142.28M
Increased by 17.31%
EPS This Year
0.19
from 0.17
Increased by 13.50%
EPS Next Year
0.29
from 0.19
Increased by 52.63%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
67.45M72.05M83.57M99.60M129.42M142.28M
Revenue Growth
13.83%6.82%15.99%19.18%29.95%9.94%
Gross Profit
41.49M42.80M50.78M61.59M83.19M91.95M
Gross Margin
61.51%59.40%60.76%61.84%64.28%64.63%
Operating Income
-27.07M-18.63M-5.60M7.73M14.30M14.08M
Net Income
-27.13M-16.54M-4.94M8.55M17.38M19.09M
EPS
----0.170.19
EPS Growth
----238.18%13.50%
Forward PE
---50.2827.8118.16
Free Cash Flow
-13.50M-9.64M9.47M9.61M4.88M25.90M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High144.6M
Avg142.3M
Low139.3M

Revenue Growth

Revenue Growth202620272028
High
11.7%
Avg
9.9%
Low
7.6%

EPS Forecast

EPS202620272028
High-
Avg0.19
Low-

EPS Growth

EPS Growth202620272028
High-
Avg
13.5%
Low-